Galena Biopharma (GALE) Misses Q3 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Roth Trims PT on Galena (GALE) Following Q3 Results, Plans to Spin Commercial Assets
November 10, 2015 9:18 AM ESTRoth Capital is trimming its price target on Buy-rated Galena Biopharma (Nasdaq: GALE) from $8 to $6 following Q3 results and plans to spin its commercial business, as... More
Galena Biopharma (GALE) Announces Presentation of GALE-301, GALE-302 Data
November 9, 2015 7:06 AM ESTGalena Biopharma (NASDAQ: GALE) announced that data from the Company's GALE-301 and GALE-302 clinical programs were presented at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland. The data presented was on the primary vaccine series (PVS) from a randomized Phase 1b trial with GALE-301 (E39) and GALE-302 (E39' variant of E39; previously named J65) that are folate binding protein-derived (FBP) peptides.
Poster #166 (abstract #156) entitled, "Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the... More
